ORAMED PHARMACEUTICALS INC. Cash and Restricted Cash
ORAMED PHARMACEUTICALS INC. (ORMP) had Cash and Restricted Cash of $15.24 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-10
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $15.24M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $13.20M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $45.95M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $52.18M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $15.24M 10-Q · filed 2026-08-10 |
| 2026-03-31 | $13.20M 10-Q · filed 2026-05-19 |
| 2025-12-31 | $45.95M 10-Q · filed 2026-08-10 |
| 2025-09-30 | $52.18M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $15.80M 10-Q · filed 2026-08-10 |
| 2025-03-31 | $74.52M 10-Q · filed 2026-05-19 |
| 2024-12-31 | $54.42M 10-Q · filed 2026-08-10 |
| 2024-09-30 | $42.10M 10-Q · filed 2025-11-13 |
| 2024-06-30 | $84.75M 10-Q · filed 2025-08-14 |
| 2024-03-31 | $18.58M 10-Q · filed 2025-05-15 |
| 2023-12-31 | $9.05M 10-K · filed 2026-03-26 |
| 2023-09-30 | $5.47M 10-Q · filed 2024-11-07 |
| 2023-06-30 | $6.77M 10-Q · filed 2024-08-14 |
| 2023-03-31 | $24.10M 10-Q · filed 2024-05-09 |
| 2022-12-31 | $40.46M 10-K · filed 2025-03-27 |
| 2022-09-30 | $33.20M 10-Q · filed 2023-11-09 |
| 2022-06-30 | $29.89M 10-Q · filed 2023-08-10 |
| 2022-03-31 | $27.97M 10-Q · filed 2023-05-11 |
| 2021-12-31 | $27.46M 10-K · filed 2024-03-06 |
| 2021-09-30 | $84.41M 10-Q · filed 2022-11-10 |
| 2021-08-31 | $77.25M 10-K · filed 2023-03-06 |
| 2021-06-30 | $79.62M 10-Q · filed 2022-08-10 |
| 2021-03-31 | $57.74M 10-Q · filed 2022-05-12 |
| 2020-12-31 | $21.63M 10-Q · filed 2022-11-10 |
| 2020-08-31 | $19.30M 10-K · filed 2023-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |